SCHEMBL5067145

SCHEMBL5067145

c1ccc2nc(OCCCN3CCOCC3)ncc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.54
KDM4E B2RXH2 3/20 0.51
MAPK1 P28482 2/20 0.48
CYP1A2 P05177 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM1 P11229 1/20 0.48
HTR2A P28223 1/20 0.48
SCN1A P35498 1/20 0.48
HTR2B P41595 1/20 0.48
KCNH2 Q12809 1/20 0.48
SCN2A Q99250 1/20 0.48
SCN3A Q9NY46 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
LMNA P02545 2/20 0.47
NPC1 O15118 1/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649077 0.88 ACP1 (0.49) KDM4EALDH1A1KCNH2HRH3KMT2A
SCHEMBL4965861 0.86 ACP1 (0.51) HTR2AKCNH2HRH3
SCHEMBL30463130 0.85 HRH3 (0.56) SIGMAR1ALDH1A1HRH3NPC1RAB9A
SCHEMBL30117493 0.81 MEN1 (0.55) MKNK1CYP1A2KMT2ACYP2D6CYP2C19
SCHEMBL28731685 0.81 MEN1 (0.53) KDM4ESIGMAR1ALDH1A1HRH3NPC1
SCHEMBL29449918 0.81 MEN1 (0.53) KDM4ESIGMAR1ALDH1A1HRH3NPC1
SCHEMBL3399864 0.79 KDM4E (0.53) KDM4EMAPK1ALDH1A1KCNH2LMNA
SCHEMBL28731663 0.78 MEN1 (0.56) MKNK1KDM4ECYP1A2ALDH1A1HRH3
SCHEMBL29937103 0.78 MKNK1 (0.41) MKNK1KDM4EALDH1A1KCNH2LMNA
SCHEMBL16245396 0.76 HRH3 (0.54) KDM4EMAPK1CYP1A2SIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699191-A1 ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF MedImmune Limited (GB) 2020-08-26 EP disclosed
CN-110559301-A Compositions containing morpholinopropoxyquinazoline derivatives 黄泳华 2019-12-13 CN disclosed
CN-110559301-A Compositions containing morpholinopropoxyquinazoline derivatives 黄泳华 2019-12-13 CN disclosed
US-10066011-B2 Antibodies directed to angiopoietin-2 and uses thereof MEDIMMUNE LIMITED (GB) 2018-09-04 US disclosed
EP-3204360-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2017-08-16 EP disclosed
WO-2016055028-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-04-14 WO disclosed
US-20150125455-A1 ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF ABGENIX, INC. 2015-05-07 US disclosed
US-8834880-B2 Antibodies directed to angiopoietin-2 and uses thereof MEDIMMUNE LIMITED (GB) 2014-09-16 US disclosed
EP-2616072-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-07-24 EP disclosed
US-20130171160-A1 ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF MEDIMMUNE LIMITED (GB) 2013-07-04 US disclosed
WO-2012035039-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-03-22 WO disclosed
US-20080267971-A1 Antibodies Directed to Angiopoietin-2 and Uses Thereof MEDIMMUNE LIMITED (GB) 2008-10-30 US disclosed
EP-1838733-A2 ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF AstraZeneca AB (SE) 2007-10-03 EP disclosed
US-20060246071-A1 Antibodies directed to angiopoietin-2 and uses thereof MEDIMMUNE LIMITED (GB) 2006-11-02 US disclosed
WO-2006068953-A2 ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF ASTRAZENECA AB (SE) 2006-06-29 WO disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 EP disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 WO disclosed